General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus
← catalyst calendarNCT06807190 · readout in 346 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
630estimated
Sites
112
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-15 | actual | When the study began enrolling |
| Primary completion | 2027-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 1
Intervention
- Drug: Insulin Icodec — also filed as Awiqli
Primary outcome
what the primary-completion date above is the date OFNumber of Adverse Reactions (ARs)
measured From baseline (week 0) to end of study (week 52)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed